Array Biopharma beats analyst expectations despite Q3 loss

BOULDER — Array Biopharma Inc. (Nasdaq: ARRY) beat analyst expectations for its third quarter earnings by 11 cents, despite posting a loss of 11 cents per share.

Array, a Boulder-based biotech company, had a net loss of nearly $22.9 million, an improvement on the same period the year prior, when the net loss was $35.3 million.

Growth Strategy Summit with Jessica Dewell

How often do you validate or revise your business’s growth strategy? If your first thought was “Not enough” Join us for the for the Growth Strategy Summit with Jessica Dewell, owner of Red Direction.

Jess advises, facilitates, and keynotes about business excellence and what it means to lead today. Adept at recognizing underutilized knowledge, she combines such information with team members’ passion to create strong connections.

Revenue was $66 million, which grew 99 percent year-over-year and beat expectations by $34.7 million.

Array added that its new drug applications for the combination of its drugs encorafenib and binimetinib to treat patients with advanced or metastatic melanoma are under review with a target action date of June 30.

BOULDER — Array Biopharma Inc. (Nasdaq: ARRY) beat analyst expectations for its third quarter earnings by 11 cents, despite posting a loss of 11 cents per share.

Array, a Boulder-based biotech company, had a net loss of nearly $22.9 million, an improvement on the same period the year prior, when the net loss was $35.3 million.